TNFRSF8 and testicular cancer: Previous studies, such as a Phase 2 clinical trial, indicated the drug’s efficacy in CD30-positive solid tumors, with mesothelioma and testicular cancer showing measurable responses, although the overall objective response rate (ORR) was relatively modest at 11%25.